Season 1: 26 Oct 2021
This week, GOLD talks to Dr Emma Roffe, Oncology Country Head, Takeda UK, and Eric Low, Founder, Myeloma UK, about the challenge of combination treatments. The two discuss a pair of whitepapers recently produced by Takeda, which uncover why challenges exist, why for so long it has been classified as ‘too hard to solve’, as well as potential solutions that could revolutionise this area of healthcare.
A little more on GOLD's guests...
Dr Emma Roffe is the Oncology Country Head, Takeda UK and Ireland, having joined the company’s Senior Leadership Team in 2018 after 15 years at Takeda. Throughout her professional career she has helped to develop a number of key oncology medicines for Takeda, and, prior to this, began her career in Clinical Research Development at AstraZeneca.
Eric Low is Owner of Eric Low Consulting, and Founder of Myeloma UK. Eric has worked with medical research charities for over 20 years and is committed to and focused on improving patient outcomes. In 2012, he was awarded an OBE for services to charity.
Historical challenges of combination treatments
Early attempts to rectify challenges
Takeda’s potential solutions
Role of other stakeholders
If you are interested in learning more about this subject, check out the below content from The GOLD Podcast and GOLD magazine: